STOCK TITAN

Stevanato Group S.p.A. - STVN STOCK NEWS

Welcome to our dedicated page for Stevanato Group S.p.A. news (Ticker: STVN), a resource for investors and traders seeking the latest updates and insights on Stevanato Group S.p.A. stock.

Stevanato Group S.p.A., founded in 1949, is a leader in creating systems, processes, and services that ensure the integrity of parenteral medicines. The company operates through two main divisions:

  • Pharmaceutical Systems (Ompi and Balda brands): Specializes in ready-to-use glass containers and bulk primary packaging such as syringes, cartridges, vials, and ampoules. Additionally, it provides high-quality, high-precision plastic solutions for diagnostic, pharmaceutical, and medical device applications.
  • Engineering Systems (Spami, Optrel, Innoscan, and SVM brands): Focuses on glass forming technology, inspection systems, assembly, packaging machines, and serialization solutions for the pharmaceutical industry.

These divisions work in close synchronization, featuring daily exchanges that ensure the Stevanato Group maintains complete control over the entire production process, from sourcing the finest raw materials to providing exceptional after-sales customer service.

The group's commitment extends beyond manufacturing; through its SGLab, the Stevanato Group offers analytical and testing services that support pharmaceutical companies in ensuring the safety, efficacy, and integrity of their products.

Stevanato Group addresses customer needs across the entire drug life cycle, including development, clinical, and commercial stages, offering an integrated, end-to-end portfolio of products, processes, and services. The company operates in two segments: Biopharmaceutical and Diagnostic Solutions, which generates key revenue and encompasses products and services for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables; and Engineering.

Geographically, the company derives the majority of its revenue from Europe, the Middle East, and Africa, positioning itself as a significant player in the global pharmaceutical, biotechnology, and life sciences industries.

Rhea-AI Summary
Stevanato Group S.p.A. (NYSE: STVN) will release its financial results for the fourth quarter and year end of 2023 on March 7, 2024. A conference call and webcast will be held to discuss the results, with pre-registration available for immediate access.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.23%
Tags
conferences earnings
-
Rhea-AI Summary
Stevanato Group S.p.A. (NYSE: STVN) has introduced two new offerings for efficient small batch pharmaceutical manufacturing: the EZ-fill® Kit and the non-GMP laboratory fill and finish service at its Technology Excellence Centers. The EZ-fill® Kit provides fast access to a customizable and versatile solution for efficiently filling small batches with high-quality injectable formulations. The surge in biopharmaceuticals treating various diseases signals significant growth potential for pharmaceutical companies. The kit brings enhanced levels of quality and safety to patients and is expected to be available commercially beginning in the second quarter of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.88%
Tags
none
-
Rhea-AI Summary
Stevanato Group S.p.A. (NYSE: STVN) will participate in the 42nd Annual J.P. Morgan Healthcare Conference from January 8-11, 2024, in San Francisco. The company will present on January 10th at 8:15 a.m.(PT) and provide a live webcast on their website. A replay of the webcast will be available for approximately 90 days after the event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.99%
Tags
conferences
Rhea-AI Summary
Stevanato Group (NYSE: STVN) Wins 2023 Pharma Innovation Award for Mavis™ Combi Visual Inspection Machine, Recognized for Excellence and Leadership in Implementing Equipment and Technology to Respond to Pharma Companies’ Needs. The Mavis™ Combi is a cutting-edge solution designed to enhance visual inspection of primary packaging and drugs, providing advanced performance, flexibility, and speed. It can handle a diverse array of glass primary containers, accurately identifying particles, cosmetic defects, and closure integrity issues, ensuring the highest standards of product quality and safety.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.12%
Tags
none
-
Rhea-AI Summary
Stevanato Group S.p.A. (NYSE: STVN) announces participation in Jefferies London Healthcare Conference, presenting on November 15, 2023 at 10:00 a.m. GMT. The live webcast and replay will be available on the Company’s website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.58%
Tags
conferences
-
Rhea-AI Summary
Stevanato Group, a leading provider of drug containment and delivery solutions, announced its Q3 2023 financial results. Revenue increased 11% to €271.4 million, with high-value solutions accounting for 32% of total revenue. Net profit increased 4% to €37.9 million, and adjusted net profit increased 6% to €40.1 million. The company reiterates its full year 2023 guidance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.19%
Tags
Rhea-AI Summary
Stevanato Group to release Q3 2023 financial results and host conference call
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.24%
Tags
conferences earnings
-
Rhea-AI Summary
Stevanato Group passes resolution at Extraordinary General Meeting of Shareholders
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.39%
Tags
none
-
Rhea-AI Summary
Stevanato Group S.p.A. to livestream Capital Markets Day on September 27, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.56%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.33%
Tags

FAQ

What is the current stock price of Stevanato Group S.p.A. (STVN)?

The current stock price of Stevanato Group S.p.A. (STVN) is $20.56 as of December 20, 2024.

What is the market cap of Stevanato Group S.p.A. (STVN)?

The market cap of Stevanato Group S.p.A. (STVN) is approximately 5.7B.

What does Stevanato Group S.p.A. specialize in?

Stevanato Group specializes in systems, processes, and services to ensure the integrity of parenteral medicines and offers products for drug containment, delivery, and diagnostics.

What are the main divisions of Stevanato Group?

The company operates through Pharmaceutical Systems and Engineering Systems divisions.

What brands fall under Stevanato's Pharmaceutical Systems division?

The Pharmaceutical Systems division includes the Ompi and Balda brands.

What services does the Engineering Systems division provide?

The Engineering Systems division offers glass forming technology, inspection systems, assembly, packaging machines, and serialization solutions.

What is the role of SGLab in Stevanato Group?

SGLab provides analytical and testing services to support pharmaceutical companies in ensuring the safety, efficacy, and integrity of their products.

Which industries does Stevanato Group serve?

Stevanato Group serves the pharmaceutical, biotechnology, and life sciences industries.

From which regions does Stevanato Group derive most of its revenue?

The majority of the group's revenue comes from Europe, the Middle East, and Africa.

How does Stevanato Group support the drug life cycle?

The company provides products, processes, and services for the development, clinical, and commercial stages of the drug life cycle.

What kind of packaging solutions does Stevanato Group offer?

Stevanato Group offers ready-to-use glass containers, syringes, cartridges, vials, ampoules, and high-precision plastic solutions.

How long has Stevanato Group been in operation?

Stevanato Group has been in operation since its founding in 1949.

Stevanato Group S.p.A.

NYSE:STVN

STVN Rankings

STVN Stock Data

5.68B
48.55M
2.04%
114.09%
1.34%
Medical Instruments & Supplies
Healthcare
Link
United States of America
Piombino Dese